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ABSTRACT: Endocannabinoids, an important class of
signaling lipids involved in health and disease, are predom-
inantly synthesized and metabolized by enzymes of the serine
hydrolase superfamily. Activity-based protein profiling
(ABPP) using fluorescent probes, such as fluorophosphonate
(FP)-TAMRA and β-lactone-based MB064, enables drug
discovery activities for serine hydrolases. FP-TAMRA and
MB064 have distinct, albeit partially overlapping, target
profiles but cannot be used in conjunction due to overlapping
excitation/emission spectra. We therefore synthesized a novel
FP-probe with a green BODIPY as a fluorescent tag and
studied its labeling profile in mouse proteomes. Surprisingly, we found that the reporter tag plays an important role in the
binding potency and selectivity of the probe. A multiplexed ABPP assay was developed in which a probe cocktail of FP-BODIPY
and MB064 visualized most endocannabinoid serine hydrolases in mouse brain proteomes in a single experiment. The
multiplexed ABPP assay was employed to profile endocannabinoid hydrolase inhibitor activity and selectivity in the mouse
brain.
The endocannabinoid system (ECS) influences manyphysiological processes in the human body, including
food intake, energy balance, motor coordination, pain
sensation, memory formation, and anxiety.1,2 The ECS has,
therefore, been under active investigation for therapeutic
exploitation.3,4 There are two main cannabinoid receptors,
CB1R and CB2R, which belong to the family of G-protein
coupled receptors. They are activated by two endogenous
ligands, i.e., anandamide (AEA) and 2-arachidonoyl glycerol
(2-AG).5,6 The production and degradation of these
endocannabinoids is mainly performed by serine hydrolases
(Figure 1A). Diacylglycerol lipase α and β (DAGL-α and -β)
are the main enzymes responsible for the biosynthesis of 2-AG
through the hydrolysis of diacylglycerol (DAG).7−9 Mono-
acylglycerol lipase (MAGL) and α,β-hydrolase-domain con-
taining enzymes 6 and 12 (ABHD6 and ABHD12) account for
99% of the 2-AG hydrolysis to arachidonic acid (AA) and
glycerol in the brain.10,11 The Ca2+-dependent biosynthesis of
endogenous AEA is mediated by the subsequent actions of
PLA2G4E12 and N-acylphosphatidylethanolamine-phospholi-
pase D (NAPE-PLD) or ABHD4,13 although other bio-
synthetic pathways have also been uncovered.3,4,14 Fatty acid
amide hydrolase (FAAH) is the key enzyme for the hydrolysis
of AEA to AA.15,16 Inhibitors of these enzymes are crucial to
investigating the biological role of the hydrolases and may
serve as drug candidates to modulate the endocannabinoid
levels in human disease.
All endocannabinoid hydrolases except NAPE-PLD belong
to the family of serine hydrolases, which consists of over 200
proteins that use a nucleophilic serine to hydrolyze ester-,
amide-, or thioesterbonds in small molecules and proteins via a
covalent acyl-protein intermediate.17,18 This mode of action is
exploited in activity-based protein profiling (ABPP).19,20
Herein, a chemical probe, typically consisting of a reactive
“warhead” and a reporter tag, reacts with the catalytically active
nucleophilic serine. The reporter tag can be either a
fluorophore to visualize the probe-protein adduct by SDS-
PAGE and fluorescence scanning21 or a biotin group to enrich
proteins from proteomes for identification by LC-MS/MS22 or
visualization by Western blotting.23 ABPP is used in drug
discovery to efficiently profile activity and selectivity of
inhibitors over a protein family in native biological samples.
The archetypical activity-based probe (ABP) for serine
hydrolases is the fluorophosphonate (FP) probe (FP-TAMRA
(1), Figure 1B), which was introduced by Liu et al. almost 20
years ago.23 This probe is widely used to study serine
hydrolases in complex proteomes.24,25 Although the FP-
based probes are known for their broad reactivity, they do
not react with all serine hydrolases.20 Most notably, DAGL-α is
among the enzymes which cannot be visualized by FP-based
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Figure 1. Endocannabinoid system, activity-based probes, and the labeling profiles of FP-TAMRA (1) and FP-BODIPY (3). (A) Schematic
overview of the main biosynthetic pathways within the endocannabinoid system. All enzymes except NAPE-PLD belong to the serine hydrolase
protein family. PC, phosphatidylcholine; PE, phosphatidylethanolamine; DAG, diacylglycerol; NAPE, N-acylphosphatidylethanolamine; AA,
arachidonic acid; PLA2G4E, phospholipase A2 group IVE; DAGL, diacylglycerol lipase; NAPE-PLD, N-acylphosphatidylethanolamine
phospholipase D; MAGL, monoacylglycerol lipase; ABHD, α,β-hydrolase-domain containing enzyme; FAAH, fatty acid amide hydrolase. (B)
Chemical structures of the four activity-based probes used in this study. (C) Direct comparison of FP-TAMRA (1) and FP-BODIPY (3) labeling
patterns of seven mouse tissue lysates.
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ABPs.26 To study DAGL-α, MB064 (2, Figure 1B), a tailored
chemical probe with a BODIPY-TMR as a fluorophore, was
developed.27 In terms of experimental efficiency with respect to
time, cost of reagents, and use of valuable biological samples, it
would be optimal to combine the commercially available FP-
TAMRA (ActivX) and MB064 in the same experiment.
However, MB064 cannot be applied in conjunction with FP-
TAMRA (1), because the excitation/emission spectra of their
fluorophores overlap. Therefore, the aim of the current study
was to synthesize, characterize, and apply a new FP-based
probe (3) with a different reporter tag (BODIPY-FL) that is
compatible with MB064. Such a multiplexed assay, using
different activity-based probes, has been shown to work for
other enzyme classes in the past.21,28,29 Here, a multiplexed
ABPP assay with ABP (3) and MB064 was developed and used
to study endocannabinoid hydrolase activity and to profile
inhibitors on activity and selectivity in mouse brain proteomes.
■ RESULTS AND DISCUSSION
FP-BODIPY probe (3) was synthesized using a previously
described method (Scheme S1).30 In addition, commercially
available FP-TAMRA (probe 1) and control compound FP-
TAMRA (4), containing the same linker as 3, were synthesized
using similar procedures (Schemes S2 and S3, respectively).
Figure 2. Concentration dependent labeling of probes 1, 3, and 4. (A) Four doses of the FP probes label the mouse brain proteome in a distinct
pattern with different affinities. (B) Quantified affinity differences among the evaluated FP probes for the 18 bands denoted in A. A # indicates a
pEC50 ≤ 6 for one of the two probes, meaning that the difference is most likely greater than the given value. A ∼ indicates a pEC50 ≤ 6 for both
probes, meaning that both probes label these proteins only at high concentrations. All quantifications assumed 100% labeling of protein at 10 μM
probe. (C) Example of the labeling pattern of band 8 (FAAH) and corresponding pEC50 curves and values.
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To obtain a broad view of serine hydrolase labeling by the
FP probes in various tissues, we first incubated FP-TAMRA
(1) and FP-BODIPY (3) with membrane and cytosol fractions
of a panel of seven mouse tissues (brain, testes, kidney, spleen,
heart, liver, and pancreas) at a concentration of 500 nM
(Figure 1C). The proteins were resolved using SDS-PAGE,
and probe-labeled proteins were visualized by fluorescent
scanning of the gel. The overall labeling profile in the various
proteomes was comparable between probes 1 and 3, but
several differences were observed, denoted with boxes. In the
brain, for example, membrane proteome FP-BODIPY (3)
labeled additional targets, including in the top left box DAGL-
α, the identity of which was confirmed by competition with
LEI104 (Figure S1).
Brain lysates were selected for further profiling of probes 1
and 3, as well as control probe 4, because the brain is the most
studied target organ of the ECS. In an initial screen, the three
ABPs were incubated with both brain membrane and soluble
proteomes (Figure 2A, Supporting Information). While the
labeling profile in the soluble proteome was not significantly
Figure 3. Illustration of the applicability of the prepared probe cocktail. (A) Dose response inhibition of FAAH using PF-04457845, covalent
irreversible, and LEI104, reversible, to test the dependency of the pIC50 determination on probe affinity and concentration. No statistical significant
differences have been found between the probe pairs (P > 0.05, two-sided Student’s t test). (B) Seven inhibitors targeted for different
endocannabinoid serine hydrolases were shown to inhibit their specific targets using the probe cocktail. (C) Dose response inhibition with LEI104
shows, in one gel, the inhibition of DAGL-α and FAAH. Quantification shows agreement of the pIC50 with literature values.
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different between the three probes, FP-BODIPY (3) labeled
various proteins at lower concentrations in the membrane
proteome. To determine the half-maximum effect (EC50)
values of serine hydrolase labeling in the membrane proteome,
the probes were dosed at a wide range of concentrations (10
pM to 10 μM), and the fluorescent signal of 18 distinct bands
was quantified and corrected for protein loading by coomassie
staining (Figures S2 and S3). To study the effect of
fluorophore and linker length on serine hydrolase labeling by
FP probes in the mouse brain membrane proteome, the change
in pEC50 of ABP 3 and 4 relative to ABP 1 was calculated
(Figure 2B and Table S1). The increased linker length did not
significantly alter the labeling efficiency for FP-TAMRA for
most proteins, except for FAAH (left plot, Figure 2C), whereas
the change in fluorophore led to a 10-fold increased potency in
labeling for several proteins (bands: 3, 8, and 18). Of note,
FAAH labeling was already visualized at 10 nM FP-BODIPY 3
and DAGL-α (band 3) at 500 nM (Figure 2C, A, respectively).
The third plot in Figure 2B, comparing probes 3 and 4, which
only differ in reporter tag, shows that almost all the difference
between the commercial FP-TAMRA probe 1 and the newly
synthesized FP-BODIPY probe 3 observed in the central plot
is due to the change in fluorophore. The most likely
explanation for the observed potency increase when changing
from TAMRA to BODIPY-FP is the strong increase in
lipophilicity. The CLogP of BODIPY-FL is 3.7 points higher
than that of TAMRA, which would make it more favorable to
stick to proteins and membranes, causing a higher local
concentration and thus better labeling. This explanation is in
line with the observation that the strongest differences are
observed in the membrane fractions and, between organs, in
the brain. Finally, the impact of the addition of a reporter tag
was visualized by preincubation with “dark” alkyne-FP (5;
Figure S4). This competitive labeling shows that alkyne-FP
only completely prevented labeling by the fluorescent probes at
5−10 μM, demonstrating the significantly reduced affinity of
the fluorophosphonate inhibitor when lacking the reporter tag.
All together, these data demonstrate that the choice of
fluorophore influences the labeling efficiency of FP-based
probes.
Next, we tested whether the activity and selectivity profile of
serine hydrolase inhibitors would be dependent on the reporter
group of the activity-based probe. To this end, we tested a
covalent irreversible FAAH inhibitor, PF-04457845,31 and a
reversible inhibitor, LEI104,27 in a competitive ABPP setting
using probe 1 (500 nM) and probe 3 (500 and 10 nM; Figure
3A). Importantly, the pIC50 values of both inhibitors were not
dependent on the fluorescent reporter group of the probe, nor
the probe concentration. This indicated that FP-BODIPY 3
can be used in a drug discovery setting to profile inhibitor
activity using ABPP.
Figure 4. Off-target profiling of β-lactam based MAGL inhibitor (6) and clinical candidate ABX-1431 in mouse brain membrane proteome. (A)
Chemical structure of 6 and 7. (B) Dose response inhibition with 6 shows several off-targets in the mouse brain membrane. (C) Dose response
inhibition with 7 shows selective MAGL inhibition in the mouse brain membrane. (D) pIC50 curves and values of 6 against MAGL. (E) pIC50
curves and values of 6 against its off-targets. (F) pIC50 curves and values of 7 against MAGL.
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Having developed two complementary probes (FP-BODIPY
(3) and MB064) with different reporter groups and distinct
labeling patterns, we tested whether they can be used in a
multiplexed ABPP assay to profile the activity and selectivity of
compounds inhibiting biosynthetic or metabolic enzymes of
the ECS.24,25,32 To this end, a cocktail of FP-BODIPY 3 (10
nM) and MB064 2 (250 nM) was incubated with mouse brain
membrane proteomes. This enabled the simultaneous visual-
ization and quantification of DAGL-α, DDHD2, ABHD16a,
FAAH, MAGL, ABHD6, and ABHD12 activities in a single
experiment (Figure 3B). Bands were identified based on
previous studies.27,33 PLA2G4E and ABHD4 can be labeled by
FP-BODIPY and MB064, respectively, but their endogenous
expression in the brain is too low to be visualized.12 A panel of
inhibitors consisting of JZL184 (MAGL),34 DH376 (DAGL-α,
ABHD6),32 THL (DAGL-α, ABHD6, ABHD12, ABHD16a,
DDHD2),35 PF-04457845 (FAAH),31 LEI104 (DAGL-α,
FAAH),27 and LEI105 (DAGL-α)33 (Figure S5) was used to
confirm the identity of each fluorescent band (Figure 3B). As a
final validation, we confirmed that the inhibitory activity of
LEI104 on DAGL-α and FAAH in this new multiplexed ABPP
assay was in line with previously reported data (Figure 3C).27
The validated assay was employed to study the selectivity
and activity of two MAGL inhibitors. First, we tested the
recently published β-lactam based MAGL inhibitor NF1819
(6; Figure 4A), which was active in several animal models of
multiple sclerosis, pain, and predator stress-induced long-term
anxiety.36,37 The target-interaction profile of NF1819 (6) was
compared to the experimental drug ABX-1431 (7), currently in
phase 2 clinical trials for the treatment of Tourette
syndrome.38−40 To this end, they were incubated at various
concentrations with mouse brain membrane proteome (Figure
4B, C and Figure S6). Inhibition of MAGL was confirmed with
a pIC50 of 8.1 ± 0.1 for 6 and 6.7 ± 0.1 for 7 (Figure 4D, F), in
accordance with previously published data.36,38 Of note, for 6,
various off-targets were observed, including ABHD6, LYPLA,
and an unidentified protein (Figure 4E). ABHD6 was inhibited
at equal potency, whereas LYPLA demonstrated a 50-fold
lower potency. FAAH labeling was only slightly reduced at
concentrations >10 μM. The target-interaction landscape of 7
is clean; even at 10 μM, no clear off-targets were observed. The
relatively small selectivity window of 6 over ABHD6 should be
taken into account during the biological evaluations of this
inhibitor as it may contribute to the rise of 2-AG levels.
In conclusion, FP-BODIPY (3) was synthesized and
characterized as a new ABP, thereby we have extended the
chemical toolbox to study serine hydrolase activity in native
biological samples. We emphasize that the choice of
fluorophore when designing ABPs can be of great influence
on labeling patterns, even for broadly reactive probes such as
fluorophosphonates. FP-BODIPY (3) in conjunction with
MB064 (2) was used to develop a multiplexed ABPP assay,
which was validated by profiling inhibitor activity and
selectivity on a broad range of endocannabinoid hydrolases
in mouse brain tissue in a single experiment. This multiplexed
ABPP assay was applied to investigate the specificity of a
recently published in vivo active MAGL inhibitor and an
experimental drug currently going through clinical trials.
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